NCT00558896 - CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis | Biotech Hunter

Enrollment

378

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

September 30, 2012

Study Completion Date

October 25, 2017

Conditions

Multiple Myeloma and Plasma Cell Neoplasm

Interventions

DRUG

dexamethasone

40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.

DRUG

pomalidomide

2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).

Trial Locations (3)

Mayo Clinic in Florida, Jacksonville

Mayo Clinic, Rochester

Mayo Clinic in Arizona, Scottsdale